American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplantation (SCT)
    Meeting Abstract

    Mishra, A.; Tamari, R.; DeZern, A. E.; Byrne, M. T.; Gooptu, M.; Chen, Y. B.; Deeg, H. J.; Gallacher, P.; Wennborg, A.; Hickman, D. K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • BTG1 mutation promotes aggressive lymphoma development by lowering the threshold to MYC activation and generating "super-competitor" B cells
    Meeting Abstract

    Mlynarczyk, C.; Teater, M.; Pae, J.; Arulraj, T.; Chin, C. R.; Wang, L.; Ersching, J.; Kots, E.; Chadburn, A.; Barin, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Six-year results from the phase 3 randomized study relevance show similar outcomes for previously untreated follicular lymphoma patients receiving lenalidomide plus rituximab (R (2)) versus rituximab-chemotherapy followed by rituximab maintenance
    Meeting Abstract

    Morschhauser, F.; Nastoupil, L.; Feugier, P.; De Colella, J. M. S.; Tilly, H.; Palomba, M. L.; Bachy, E.; Fruchart, C.; Libby, E.; Casasnovas, R. O.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Efficacy and safety results from ascembl, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: Update after 48 weeks
    Meeting Abstract

    Mauro, M. J.; Minami, Y.; Rea, D.; Hochhaus, A.; Lomaia, E.; Voloshin, S.; Turkina, A. G.; Kim, D. W.; Apperley, J. F.; Cortes, J. E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • End of treatment peripheral blood TCR evaluation for minimal residual disease evaluation in peripheral T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Jacobsen, E. D.; Fehniger, T. A.; Kahl, B. S.; Bartlett, N. L.; Cashen, A. F.; Ghobadi, A.; Reagan, B.; Fischer, A.; Moskowitz, A. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Post-transplant inotuzumab ozogamicin for acute lymphoblastic leukemia
    Meeting Abstract

    Metheny, L. 3rd; Sobecks, R. M.; Cho, C.; Caimi, P. F.; Majhail, N. S.; Otegbeye, F.; Boughan, K. M.; Cooper, B. W.; Galloway, E.; Gallogly, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clonotype-immunophenotype relationships in TET2 and IDH-mutant myeloid transformation
    Meeting Abstract

    Miles, L. A.; Bowman, R. L.; Delgaudio, N.; Robinson, T.; Carroll, M. P.; Meyer, S. E.; Levine, R. L.
    Blood (2021)

    Fulltext@MSK | Save
  • Molecular evolution of classical Hodgkin lymphoma revealed though whole genome sequencing of Hodgkin and Reed-Sternberg cells
    Meeting Abstract

    Maura, F.; Imielinski, M.; Xiang, J. Z.; Binder, B.; Eng, K.; Uppal, M.; He, F.; Zhang, W.; Gao, Q.; Park, S. I.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Duration of objective responses for patients with indolent non-Hodgkin lymphoma discontinuing treatment before progression: Analysis from the phase III CHRONOS-3 trial comparing copanlisib plus rituximab with placebo plus rituximab
    Meeting Abstract

    Matasar, M. J.; Capra, M.; Özcan, M.; Lv, F.; Li, W.; Yañez, E.; Sapunarova, K.; Lin, T.; Jin, J.; Jurczak, W.; more...
    Blood (2021)

    Fulltext@MSK | Save